

25 July 2022

Statement pursuant to Listing Rule 4.7C.3

Mach7 Technologies Limited (**M7T** or **the Company**), advises that in accordance with Listing Rule 4.7C.3, and as noted in Item 6 of the Appendix 4C Cashflow Statement lodged by the Company with the Australian Securities Exchange (ASX) on 21 July 2022, payments to related parties and their associates during the quarter ended 30 June 2022 were \$215k. These payments related to:

- payment of \$85,925 for Director's fees and superannuation for the quarter; and
- payment of \$128,770 for Executive Director's salary and superannuation for the quarter.

Released on authority of the Board by:

David Chambers
Chairman of the Board

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative data management solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced clinical viewing and optimized vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit [Mach7t.com](https://www.mach7t.com).

For more information, contact:

CFO, Mach7:

Steve Parkes
steve.parkes@mach7t.com

Investor Relations:

Simon Hinsley
NWR Communications
+61 (0) 401 809 653
simon@nwrcommunications.com.au

Registered Office:

Level 4 | 100 Albert Road
South Melbourne, VIC